Swissmedic
REGULATORY UPDATE
Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Published: 10/1/2026Detected: 10/1/2026
Summary preview
Clarifies or updates Swiss guidance on the conditions and documentation expectations for importing human medicinal products under Art. 14 para. 2 and 3 TPA (parallel import).
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
safety
labeling
#parallel import
#TPA Art. 14
#importation of medicinal products
#dossier requirements
#quality documentation
Official Source Document Source Verified
Access the original document directly from SWISSMEDIC.
More from Swissmedic
- Adaptations required for issuing establishment licences and GMP certificates for manufacturers of active substances10/1/2026
- Revision of the Guidance document Authorisation Biosimilar10/1/2026
- Swissmedic Portal Release – New Features Available from 23 September 20269/24/2026
- I-SMI.TI.22e Notifications according to Article 41, MPLO9/23/2026
- ElViS 2.09/4/2026